Geraldine J Ooi1,2, Paul R Burton3,4, Jacqueline Bayliss5,6, Arthe Raajendiran5,6, Arul Earnest7, Cheryl Laurie3,4, William W Kemp8, Catriona A McLean9, Stuart K Roberts8, Matthew J Watt5,6, Wendy A Brown3,4. 1. Centre for Obesity Research and Education, Central Clinical School, Monash University, Level 6, 99 Commercial Road, Melbourne, 3181, Australia. geraldineooi@gmail.com. 2. Department of General Surgery, The Alfred Hospital, Melbourne, Australia. geraldineooi@gmail.com. 3. Centre for Obesity Research and Education, Central Clinical School, Monash University, Level 6, 99 Commercial Road, Melbourne, 3181, Australia. 4. Department of General Surgery, The Alfred Hospital, Melbourne, Australia. 5. Department of Physiology, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Australia. 6. Department of Physiology, School of Biomedical Sciences, Melbourne University, Parkville, Australia. 7. Biostatistics, School of Public Health and Preventative Medicine, Monash University, Melbourne, Australia. 8. Department of Gastroenterology, The Alfred Hospital, Melbourne, Australia. 9. Department of Anatomical Pathology, The Alfred Hospital, Melbourne, Australia.
Abstract
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD), driven by the obesity epidemic, has become the most common form of liver disease. Despite this, there is controversy regarding the prevalence and severity of NAFLD in obesity. Obesity-related factors, such as increasing adiposity, metabolic disease and inflammation, may influence prevalence. We therefore prospectively measured NAFLD prevalence in obesity and studied factors associated with NAFLD. MATERIALS AND METHODS: We recruited consecutive bariatric patients. Intraoperative liver biopsies were taken. The liver, adipose tissue and serum were collected to measure inflammation. Adipocyte cell size was measured. NAFLD severity was correlated to body mass index (BMI), metabolic health and adipose characteristics. RESULTS: There were 216 participants; BMI 45.9 ± 8.9 kg/m2, age 44.4 ± 12.1 years, 75.5% female. Overall NAFLD prevalence was 74.1%, with 17.1% having non-alcoholic steatohepatitis (NASH) and/or steatofibrosis. Odds of NASH/steatofibrosis increased independently with BMI category (odds ratio (OR) 2.28-3.46, all p < 0.05) and metabolic disease (OR 3.79, p = 0.003). These odds markedly increased when both super obesity (BMI > 50) and metabolic disease were present (OR 9.71, p < 0.001). NASH/steatofibrosis prevalence was significantly greater with diabetes, hypertension and dyslipidemia. Although greater visceral adipocyte hypertrophy was evident in NASH/steatofibrosis, there was no significant association between adipose inflammation and NASH/steatofibrosis. CONCLUSION: NAFLD remains endemic in obesity; however, NASH/steatofibrosis are less common than previously reported. Worsening obesity and metabolic disease increase odds of NAFLD independently, with substantially compounded effect with both. These observations may help with risk stratification in obese populations. We were unable to delineate clear associations between adipose inflammation and NASH/steatofibrosis in this obese population. TRIAL REGISTRATION: Australian Clinical Trials Registry ( ACTRN12615000875505 ).
BACKGROUND:Non-alcoholic fatty liver disease (NAFLD), driven by the obesity epidemic, has become the most common form of liver disease. Despite this, there is controversy regarding the prevalence and severity of NAFLD in obesity. Obesity-related factors, such as increasing adiposity, metabolic disease and inflammation, may influence prevalence. We therefore prospectively measured NAFLD prevalence in obesity and studied factors associated with NAFLD. MATERIALS AND METHODS: We recruited consecutive bariatric patients. Intraoperative liver biopsies were taken. The liver, adipose tissue and serum were collected to measure inflammation. Adipocyte cell size was measured. NAFLD severity was correlated to body mass index (BMI), metabolic health and adipose characteristics. RESULTS: There were 216 participants; BMI 45.9 ± 8.9 kg/m2, age 44.4 ± 12.1 years, 75.5% female. Overall NAFLD prevalence was 74.1%, with 17.1% having non-alcoholic steatohepatitis (NASH) and/or steatofibrosis. Odds of NASH/steatofibrosis increased independently with BMI category (odds ratio (OR) 2.28-3.46, all p < 0.05) and metabolic disease (OR 3.79, p = 0.003). These odds markedly increased when both super obesity (BMI > 50) and metabolic disease were present (OR 9.71, p < 0.001). NASH/steatofibrosis prevalence was significantly greater with diabetes, hypertension and dyslipidemia. Although greater visceral adipocyte hypertrophy was evident in NASH/steatofibrosis, there was no significant association between adipose inflammation and NASH/steatofibrosis. CONCLUSION: NAFLD remains endemic in obesity; however, NASH/steatofibrosis are less common than previously reported. Worsening obesity and metabolic disease increase odds of NAFLD independently, with substantially compounded effect with both. These observations may help with risk stratification in obese populations. We were unable to delineate clear associations between adipose inflammation and NASH/steatofibrosis in this obese population. TRIAL REGISTRATION: Australian Clinical Trials Registry ( ACTRN12615000875505 ).
Authors: Naga Chalasani; Zobair Younossi; Joel E Lavine; Anna Mae Diehl; Elizabeth M Brunt; Kenneth Cusi; Michael Charlton; Arun J Sanyal Journal: Gastroenterology Date: 2012-05-15 Impact factor: 22.682
Authors: Elizabeth M Brunt; David E Kleiner; Laura A Wilson; Patricia Belt; Brent A Neuschwander-Tetri Journal: Hepatology Date: 2011-02-11 Impact factor: 17.425
Authors: Johannie du Plessis; Jos van Pelt; Hannelie Korf; Chantal Mathieu; Bart van der Schueren; Matthias Lannoo; Tom Oyen; Baki Topal; Gary Fetter; Simon Nayler; Tessa van der Merwe; Petra Windmolders; Luc Van Gaal; An Verrijken; Guy Hubens; Martin Gericke; David Cassiman; Sven Francque; Frederik Nevens; Schalk van der Merwe Journal: Gastroenterology Date: 2015-05-28 Impact factor: 22.682
Authors: Lydia A Lynch; Jean M O'Connell; Anna K Kwasnik; Thomas J Cawood; Cliona O'Farrelly; Donal B O'Shea Journal: Obesity (Silver Spring) Date: 2008-12-18 Impact factor: 5.002
Authors: T J I De Munck; P L M Verhaegh; J Verbeek; J Verheij; J W Greve; D M A E Jonkers; A A M Masclee; G H Koek Journal: Obes Surg Date: 2019-03 Impact factor: 4.129
Authors: Julie S Pedersen; Marte O Rygg; Karoline Chrøis; Elahu G Sustarsic; Zach Gerhart-Hines; Nicolai J Wever Albrechtsen; Reza R Serizawa; Viggo B Kristiansen; Astrid L Basse; Astrid E B Boilesen; Beth H Olsen; Torben Hansen; Lise Lotte Gluud; Sten Madsbad; Steen Larsen; Flemming Bendtsen; Flemming Dela Journal: Nat Commun Date: 2022-05-25 Impact factor: 17.694
Authors: Jacqueline Bayliss; Geraldine J Ooi; William De Nardo; Yazmin Johari Halim Shah; Magdalene K Montgomery; Catriona McLean; William Kemp; Stuart K Roberts; Wendy A Brown; Paul R Burton; Matthew J Watt Journal: Front Endocrinol (Lausanne) Date: 2021-03-04 Impact factor: 5.555
Authors: Magdalene K Montgomery; Jacqueline Bayliss; Shuai Nie; William De Nardo; Stacey N Keenan; Paula M Miotto; Hamzeh Karimkhanloo; Cheng Huang; Ralf B Schittenhelm; Anthony S Don; Andrew Ryan; Nicholas A Williamson; Geraldine J Ooi; Wendy A Brown; Paul R Burton; Benjamin L Parker; Matthew J Watt Journal: Nat Commun Date: 2022-03-10 Impact factor: 14.919